ReviewFrontiers in oncology2022
Targeting ALK Rearrangements in NSCLC: Current State of the Art.
Ling Peng et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
40 papers cite it
this paperpooled itcites it
ReviewFrontiers in oncology2022
Ling Peng et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.